Mentice AB (publ) (STO:MNTC)
| Market Cap | 420.48M +13.4% |
| Revenue (ttm) | 303.13M +15.9% |
| Net Income | -4.61M |
| EPS | -0.16 |
| Shares Out | 28.13M |
| PE Ratio | n/a |
| Forward PE | 212.90 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 39,371 |
| Open | 14.90 |
| Previous Close | 14.75 |
| Day's Range | 14.05 - 14.95 |
| 52-Week Range | 8.50 - 18.00 |
| Beta | 0.46 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 23, 2026 |
About Mentice AB
Mentice AB (publ), together with its subsidiaries, develops, sells, and markets solutions for training and decision support in the clinical area of interventional angiography in cardiology, neurology, vascular surgery, and radiology. It operates through the Mentice VIST, Physical Sim, and Ankyras segments. The company offers virtual simulation products, including VR simulator platforms; procedural learning models; peripheral vascular; patient simulator accessories and extensions for endovascular therapies; and Angiosuite integrations, such as t... [Read more]
Financial Performance
In 2025, Mentice AB's revenue was 279.09 million, a decrease of -3.87% compared to the previous year's 290.33 million. Losses were -32.33 million, 75.5% more than in 2024.
Financial StatementsNews
Mentice AB Earnings Call Transcript: Q2 2026
Q2 saw robust revenue and order intake growth, with improved EBITDA and a strengthened cash position. The order book is healthy, driven by MedTech demand, and management expects sustained profitability and growth, supported by new partnerships and a focus on AI and robotics.
Mentice AB Quarterly report: Q2 2026
Mentice AB has published its Q2 2026 quarterly earnings report on July 23, 2026.
Mentice AB Slides: Q2 2026
Mentice AB has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 23, 2026.
Mentice AB (OSTO:MNTC) Q2 2026: Everything You Need To Know Ahead Of Earnings
Mentice AB (OSTO:MNTC) Q2 2026: Everything You Need To Know Ahead Of Earnings
Mentice AB Earnings Call Transcript: Q1 2026
Q1 delivered 26% organic revenue growth and a 50% increase in order intake, with strong momentum across MedTech and healthcare systems segments. EBITDA improved but remained negative due to seasonality, while cost discipline and a robust pipeline support a positive outlook.
Mentice AB Quarterly report: Q1 2026
Mentice AB has published its Q1 2026 quarterly earnings report on May 7, 2026.
Mentice AB (OSTO:MNTC) Q1 2026 Earnings Report Preview: What to Expect
Mentice AB (OSTO:MNTC) Q1 2026 Earnings Report Preview: What to Expect
Mentice AB Transcript: DNB Carnegie Healthcare Seminar 2026
The presentation highlighted strong growth in simulation solutions for minimally invasive procedures, with a broadened customer base and robust financial performance. Strategic investments in advanced training and digital twin technology aim to drive further expansion and profitability.
Mentice AB Earnings Call Transcript: Q4 2025
Q4 saw strong organic growth in sales and order intake, with EBITDA margin rising to 25%. The Americas and MDI segment led performance, while cost control and R&D focus position the company for continued growth in 2026.
Mentice AB Quarterly report: Q4 2025
Mentice AB has published its Q4 2025 quarterly earnings report on February 26, 2026.
Mentice AB Annual report: Q4 2025
Mentice AB has published its Q4 2025 annual report on February 26, 2026.
Mentice AB Earnings Call Transcript: Q3 2025
Q3 saw 22% year-over-year net sales growth, driven by the medical device industry in Americas and EMEA, with improved EBITDA margin from cost reductions. A successful rights issue and the launch of a portable simulation system support future growth, while hospital and APAC segments face challenges.
Mentice AB Quarterly report: Q3 2025
Mentice AB has published its Q3 2025 quarterly earnings report on November 6, 2025.